Vasculitis & polymyalgia rheumatica
[ 68 Ga]Ga-DOTA-Siglec-9 PET/CT in newly diagnosed giant cell arteritis: an inflammation-specific, treatment-responsive molecular imaging biomarker
Authors' conclusion
This first-in-human study demonstrates that [68Ga]Ga-DOTA-Siglec-9 PET/CT detects vascular inflammation in GCA and shows attenuation with prednisolone exposure.
Study context
- Population
- Patients with newly diagnosed and relapsing giant cell arteritis (GCA), and controls
- Comparison
- Newly diagnosed GCA vs relapsing GCA
- Newly diagnosed GCAn = Eight
- Relapsingn = eightreference
- Controlsn = eight
- Outcome
- Vascular [68Ga]Ga-DOTA-Siglec-9 tracer uptake and associations
Main finding
As reported in the abstract
- Subclavian artery intima-media thickness (US) vs tracer uptake, r=0.67
- p=0.035
- Prednisolone exposure vs vascular uptake, SUVmean r=−0.51
- p=0.043
- Prednisolone exposure vs vascular uptake, SUVmax r=−0.62
- p=0.010
- MMP2 and MMP3 negatively associated with vascular uptake (eg, aortic arch r=−0.59)
- p=0.027
Further findings
| Outcome | P value |
|---|---|
| sVAP-1 levelsNewly diagnosed GCA vs Relapsing · sVAP-1 reduced in newly diagnosed GCA | P = 0.0145 |
| sVAP-1 levelsNewly diagnosed GCA vs Controls · sVAP-1 reduced in newly diagnosed GCA | P = 0.0446 |
- sVAP-1 levels — sVAP-1 vs MMP2, r=−0.56
- p=0.037
- sVAP-1 levels — sVAP-1 vs MMP9, r=−0.47
- p=0.089
Original publication
[ 68 Ga]Ga-DOTA-Siglec-9 PET/CT in newly diagnosed giant cell arteritis: an inflammation-specific, treatment-responsive molecular imaging biomarker. RMD Open. Published 11 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →